论文部分内容阅读
目的探讨吡格列酮对慢性肾脏病(CKD)患者血管内皮功能和肾病进展的影响。方法采用随机、对照的方法选取非糖尿病的慢性肾脏病3~4期约60例,均予常规治疗,处理组27例患者同时加吡格列酮片(30 mg/d),治疗4个月,观察治疗前及治疗4个月后的肱动脉内皮依赖性舒张功能(FMD)、超敏C反应蛋白(hs-CRP)、血清肌酐(Scr)、尿蛋白定量(Upr)等指标的变化。结果吡格列酮处理组FMD改善、hs-CRP、Scr、Upr下降,与对照组比较差异有统计学意义(P<0.05或0.01),且内皮依赖性血管舒张率升高与hs-CRP水平的降低呈负相关。结论吡格列酮可以减轻非糖尿病CKD患者炎症,改善血管内皮功能,延缓肾病进展。
Objective To investigate the effect of pioglitazone on vascular endothelial function and nephropathy in patients with chronic kidney disease (CKD). Methods A randomized, controlled trial was conducted in about 60 patients with stage 3 ~ 4 chronic non-diabetic CKD. All of them were given routine treatment. In the treatment group, 27 patients were treated with pioglitazone (30 mg / d) for 4 months. The changes of brachial artery endothelium-dependent vasodilation (FMD), hs-CRP, serum creatinine (Scr), and urinary proteinuria (UPr) were measured before and 4 months after treatment. Results Pioglitazone improved FMD, hs-CRP, Scr, Upr decreased compared with the control group (P <0.05 or 0.01), and endothelium-dependent vasodilatation and hs-CRP levels decreased Negative correlation. Conclusion Pioglitazone can reduce the inflammation of non-diabetic patients with CKD, improve endothelial function and delay the progression of nephropathy.